1080650-02-7

Basic information

• Product Name: 4,6-diMethyl-5-nitropyriMidin-2-ol
• Synonyms: 4,6-diMethyl-5-nitropyriMidin-2-ol;2-Hydroxy-4,6-diMethyl-5-nitropyriMidine
• CAS NO: 1080650-02-7
• Molecular Formula: C₆H₇N₃O₃
• Molecular Weight: 169.13808
• Mol File: 1080650-02-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4,6-diMethyl-5-nitropyriMidin-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-diMethyl-5-nitropyriMidin-2-ol(1080650-02-7)
• EPA Substance Registry System: 4,6-diMethyl-5-nitropyriMidin-2-ol(1080650-02-7)

Safety Data

• Hazardous Substances Data: 1080650-02-7(Hazardous Substances Data)

Usage

General Description

4,6-diMethyl-5-nitropyriMidin-2-ol is a chemical compound with the molecular formula C8H9N3O3. It is a derivative of pyrimidine and has two methyl groups and a nitro group attached to the pyrimidine ring. 4,6-diMethyl-5-nitropyriMidin-2-ol has a yellow crystalline appearance and is used in various chemical and pharmaceutical applications. It is known to have mutagenic and genotoxic effects and should be handled with caution. 4,6-diMethyl-5-nitropyriMidin-2-ol is also used as a reagent in organic synthesis and in the production of certain pharmaceutical drugs. It is important to handle and store this compound properly to avoid any potential hazards.

Upstream product

• 123-54-6 acetylacetone 
• 34289-60-6 4,6-dimethyl-2-hydroxy-pyrimidine hydrochloride 
• 108-79-2 4,6-dimethyl-2(1H)-pyrimidinone 

Downstream Products

• 90856-77-2 4,6-dimethylpyrimidin-5-ylamine 

Relevant articles and documents

NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

PYRAZOLOPYRIDINES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM

The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said com- pounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.